Novartis Announces Remibrutinib Lowers Annualized Relapse Rate By 35.2%, 31.2% In Phase III REMODEL-1, REMODEL-2 Studies To Treat Relapsing Multiple Sclerosis

뉴스 본문을 불러오고 있어요.

Novartis Announces Remibrutinib Lowers Annualized Relapse Rate By 35.2%, 31.2% In Phase III REMODEL-1, REMODEL-2 Studies To Treat Relapsing Multiple Sclerosis | 웨이프 WAPE

Novartis Announces Remibrutinib Lowers Annualized Relapse Rate By 35.2%, 31.2% In Phase III REMODEL-1, REMODEL-2 Studies To Treat Relapsing Multiple Sclerosis

기사 요약

관련 종목

댓글 —